Elizabeth Webster's questions to Taysha Gene Therapies Inc (TSHA) leadership • Q2 2024
Question
Elizabeth Webster, on for Salveen Richter, inquired about the status of dialogue with regulatory authorities.
Answer
CEO Sean Nolan reported that Taysha has an upcoming Type B meeting with the FDA, a result of its RMAT designation. The key goals are to align on the cadence of interactions, share incoming clinical and natural history data in near real-time, and use this information to inform the trial design and endpoints for Part B of the study. He indicated that updates on this front would be provided in the coming quarter.